Seastar Medical targets about $2M 2026 QUELIMMUNE revenue while aiming to finish NEUTRALIZE-AKI enrollment by end of 2026
Source: SeekingAlpha
2026-05-13 18:51:32 ET
More on SeaStar Medical Holding
- SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
- SeaStar Medical Holding Corporation (ICU) Q4 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on SeaStar Medical Holding
- Historical earnings data for SeaStar Medical Holding
- Financial information for SeaStar Medical Holding
Read the full article on Seeking Alpha
For further details see:
Seastar Medical targets about $2M 2026 QUELIMMUNE revenue while aiming to finish NEUTRALIZE-AKI enrollment by end of 2026
SeaStar Medical Holding Corporation Warrant
NASDAQ: ICUCW
ICUCW Trading
-5.94% G/L:
$0.0206 Last:
36,510 Volume:
$0.0185 Open:
ICUCW Latest News
ICUCW Stock Data
$8,688,238
3,568,666
N/A
17
N/A
Biotechnology & Life Sciences
Healthcare
US
Denver
